These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 23054215)
1. The spectrum of urological malignancy in Lynch syndrome. Barrow PJ; Ingham S; O'Hara C; Green K; McIntyre I; Lalloo F; Hill J; Evans DG Fam Cancer; 2013 Mar; 12(1):57-63. PubMed ID: 23054215 [TBL] [Abstract][Full Text] [Related]
2. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421 [TBL] [Abstract][Full Text] [Related]
3. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444 [TBL] [Abstract][Full Text] [Related]
4. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884 [TBL] [Abstract][Full Text] [Related]
5. Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Wischhusen JW; Ukaegbu C; Dhingra TG; Uno H; Kastrinos F; Syngal S; Yurgelun MB Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):193-199. PubMed ID: 31615790 [TBL] [Abstract][Full Text] [Related]
7. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828 [TBL] [Abstract][Full Text] [Related]
8. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289 [TBL] [Abstract][Full Text] [Related]
9. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Geary J; Sasieni P; Houlston R; Izatt L; Eeles R; Payne SJ; Fisher S; Hodgson SV Fam Cancer; 2008; 7(2):163-72. PubMed ID: 17939062 [TBL] [Abstract][Full Text] [Related]
10. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731 [TBL] [Abstract][Full Text] [Related]
11. Risks of less common cancers in proven mutation carriers with lynch syndrome. Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106 [TBL] [Abstract][Full Text] [Related]
12. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Barrow E; Robinson L; Alduaij W; Shenton A; Clancy T; Lalloo F; Hill J; Evans DG Clin Genet; 2009 Feb; 75(2):141-9. PubMed ID: 19215248 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population. Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498 [TBL] [Abstract][Full Text] [Related]
14. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Guindalini RS; Win AK; Gulden C; Lindor NM; Newcomb PA; Haile RW; Raymond V; Stoffel E; Hall M; Llor X; Ukaegbu CI; Solomon I; Weitzel J; Kalady M; Blanco A; Terdiman J; Shuttlesworth GA; Lynch PM; Hampel H; Lynch HT; Jenkins MA; Olopade OI; Kupfer SS Gastroenterology; 2015 Nov; 149(6):1446-53. PubMed ID: 26248088 [TBL] [Abstract][Full Text] [Related]
15. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. International Mismatch Repair Consortium Lancet Oncol; 2021 Jul; 22(7):1014-1022. PubMed ID: 34111421 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703 [TBL] [Abstract][Full Text] [Related]
17. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. Lin KM; Shashidharan M; Thorson AG; Ternent CA; Blatchford GJ; Christensen MA; Watson P; Lemon SJ; Franklin B; Karr B; Lynch J; Lynch HT J Gastrointest Surg; 1998; 2(1):67-71. PubMed ID: 9841970 [TBL] [Abstract][Full Text] [Related]
18. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Dominguez-Valentin M; Sampson JR; Seppälä TT; Ten Broeke SW; Plazzer JP; Nakken S; Engel C; Aretz S; Jenkins MA; Sunde L; Bernstein I; Capella G; Balaguer F; Thomas H; Evans DG; Burn J; Greenblatt M; Hovig E; de Vos Tot Nederveen Cappel WH; Sijmons RH; Bertario L; Tibiletti MG; Cavestro GM; Lindblom A; Della Valle A; Lopez-Köstner F; Gluck N; Katz LH; Heinimann K; Vaccaro CA; Büttner R; Görgens H; Holinski-Feder E; Morak M; Holzapfel S; Hüneburg R; Knebel Doeberitz MV; Loeffler M; Rahner N; Schackert HK; Steinke-Lange V; Schmiegel W; Vangala D; Pylvänäinen K; Renkonen-Sinisalo L; Hopper JL; Win AK; Haile RW; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Wadt K; Therkildsen C; Okkels H; Ketabi Z; Moreira L; Sánchez A; Serra-Burriel M; Pineda M; Navarro M; Blanco I; Green K; Lalloo F; Crosbie EJ; Hill J; Denton OG; Frayling IM; Rødland EA; Vasen H; Mints M; Neffa F; Esperon P; Alvarez K; Kariv R; Rosner G; Pinero TA; Gonzalez ML; Kalfayan P; Tjandra D; Winship IM; Macrae F; Möslein G; Mecklin JP; Nielsen M; Møller P Genet Med; 2020 Jan; 22(1):15-25. PubMed ID: 31337882 [TBL] [Abstract][Full Text] [Related]
19. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Pande M; Wei C; Chen J; Amos CI; Lynch PM; Lu KH; Lucio LA; Boyd-Rogers SG; Bannon SA; Mork ME; Frazier ML Fam Cancer; 2012 Sep; 11(3):441-7. PubMed ID: 22714864 [TBL] [Abstract][Full Text] [Related]
20. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]